Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.

Yoichi Naito Yasutoshi Kuboki Masafumi Ikeda Kenichi Harano Nobuaki Matsubara Shigeyuki Toyoizumi Yuko Mori Natsuki Hori Takashi Nagasawa Takahiro Kogawa

Published in: Investigational new drugs (2021)

Single-agent talazoparib was well tolerated and had preliminary antitumor activity in Japanese patients with advanced solid tumors. ClinicalTrials.gov identifier: NCT03343054 (November 17, 2017).

Keyphrases

dna damage
open label
dna repair
clinical trial
oxidative stress
study protocol